Benefit assessment in Germany: implications for price discounts-Reference-Cited by-同舟云学术

Benefit assessment in Germany: implications for price discounts

Published:2016-08-02 Issue:1 Volume:6 Page:
ISSN:2191-1991
Container-title:Health Economics Review
language:en
Short-container-title:Health Econ Rev

Author:

Theidel Ulrike^ORCID,von der Schulenburg J-Matthias Graf

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Link

http://link.springer.com/content/pdf/10.1186/s13561-016-0109-3.pdf

Reference26 articles.

1. IQWiG. Allgemeine Methoden. 2015. https://www.iqwig.de/de/methoden/methodenpapier.3020.html . Accessed 15 Feb 2016.

2. Ruof J, Schwartz FW, Schulenburg JM, Dintsios CM. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. Eur J Health Econ. 2014;15(6):577–89.

3. Horn H, Nink K, Mcgauran N, Wieseler B. Early benefit assessment of new drugs in Germany—results from 2011 to 2012. Health Policy. 2014;116(2–3):147–53.

4. Henke K-D. Wert und Preisermittlung bei Innovationen: Eine ökonomische Analyse zu den Verhandlungskriterien beim AMNOG. 2014. http://docplayer.org/308462-Wert-und-preisermittlung-bei-innovationen-eine-oekonomische-analyse-zu-den-verhandlungskriterien-beim-amnog.html . Accessed 15 Feb 2016.

5. Greiner W, Witte J. AMNOG-Report 2015 - Arzneimittelreform auf dem Prüfstand. DAK-Gesundheit. 2015. https://www.dak.de/dak/download/Praesentation_des_AMNOG-Reports-1574986.pdf . Accessed 24 May 2015.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease;Journal of Clinical Medicine;2024-07-22

2. HTA decision-making for drugs for rare diseases: comparison of processes across countries;Orphanet Journal of Rare Diseases;2022-07-08

3. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence;Health Policy;2022-02

4. Qualität der Arzneimittelversorgung – Theoretischer und konzeptueller Rahmen;Arzneimittel-Kompass 2022;2022

5. The Assessment of the Innovativeness of a New Medicine in Italy;Frontiers in Medicine;2021-12-08